July 17 (Reuters) – GSK on Friday said it had decided not to develop its experimental drug to treat refractory chronic cough further after it did not meet one of its main goals in a late-stage trial.
Shares dipped 2% to 1,916 pence after the announcement.
Camlipixant’S 50 mg dose met its main goal to reduce 24-hour cough frequency compared to a placebo in 12 weeks when used twice daily, but failed to reach statistical significance in the same goal at week 24, GSK said.
(Reporting by Prerna Bedi in Bengaluru; Editing by Sonia Cheema)
Comments